Related Experiment Video
Updated: Aug 11, 2026
12:52
Use of Shigella flexneri to Study Autophagy-Cytoskeleton Interactions
Published on: September 9, 2014
Strategy for cross-protection among Shigella flexneri serotypes
F R Noriega1, F M Liao, D R Maneval
1Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA. fnoriega@us.pmc-vacc.com
Infection and Immunity
|January 23, 1999
Summary
A novel vaccine strategy using two Shigella flexneri serotypes (2a and 3a) demonstrated broad cross-protection in animal models. This approach targets major antigenic factors for enhanced Shigella vaccine development.
Area of Science:
- Microbiology
- Immunology
- Vaccine Development
Background:
- Shigella flexneri, a leading cause of bacterial dysentery, exhibits significant serotype diversity.
- Lipopolysaccharide (LPS) structure and antigenicity are key targets for developing broad-spectrum Shigella vaccines.
Purpose of the Study:
- To design and evaluate a vaccine strategy for broad cross-protection against Shigella group B using two specific serotypes.
- To assess the immunogenicity and protective efficacy of novel attenuated Shigella flexneri strains.
Main Methods:
- Development of attenuated Shigella flexneri 2a (CVD 1207) and 3a (CVD 1211) strains.
- Immunization of guinea pigs with a mixture of the two attenuated strains.
- Challenge studies using virulent wild-type Shigella flexneri serotypes and serological assays (ELISA, immunoblotting, slide agglutination).
Main Results:
- Immunization induced serum and mucosal antibodies cross-reactive with multiple S. flexneri serotypes (excluding serotype 6).
- The vaccine combination provided significant protection against challenge with S. flexneri serotypes 1b, 2b, 5b, and Y.
- Protection was not observed against S. flexneri serotypes 1a, 4b, and 6.
Conclusions:
- A bivalent vaccine strategy using S. flexneri 2a and 3a demonstrates potential for broad cross-protection against Shigella group B.
- The study highlights the importance of targeting major antigenic group factors for effective Shigella vaccine design.
- Further research is warranted to optimize vaccine efficacy against all targeted serotypes.
Related Concept Videos
00:42Cross-reactivity
Overview
01:18Bacterial Gastroenteritis
Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid receptor...